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Summary The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of
various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of
advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-
based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and
unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-
platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are
equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.
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Health care professionals and patients alike are becoming increas-
ingly aware of the need to make medical decisions on the basis of
up-to-date, objective and unbiased research (Chalmers and
Haynes, 1994). The most reliable information results from
randomized controlled trials (RCTs). Unfortunately, most RCTs,
including those conducted in ovarian cancer, have been too small
to demonstrate moderate treatment benefits with reliability, and
many results have been inconclusive or contradictory. The
Advanced Ovarian Cancer Trialists Group (AOCTG) recognized
that the best means of synthesizing such randomized evidence is
by systematic meta-analysis. In 1988, five meta-analyses of
chemotherapy in advanced ovarian cancer using updated indi-
vidual patient data were initiated. The first results were published
in 1991 (AOCTG, 1991). The AOCTG recognized the importance
of updating these results especially for the comparison of carbo-
platin and cisplatin, in which the data were relatively immature.
The comparison of platinum analogues was considered of such
clinical importance that further new investigations were initiated
to identify whether any particular type ofwomen or tumour would
benefit more from either cisplatin- or carboplatin-based
chemotherapy.
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PATIENTS AND METHODS
Trials were eligible for inclusion provided they examined first-line
chemotherapy for advanced ovarian cancer, were properly
randomized and made one ofthe treatment comparisons described
below. Trials were identified by bibliographic searches using
MEDLINE and CancerLit, by hand searching relevant meeting
proceedings and by consulting trial registers (AOCTG, 1991).
Both published and unpublished trials were included and updated
data were sought for all randomized patients. All data were
checked thoroughly and the final database entries for each trial
were verified by the responsible trialist or data centre.
All analyses were based on intention to treat. Survival analyses
were stratified by trial, and the log-rank expected number ofdeaths
and variance was used to calculate individual and pooled hazard
ratios (HRs) using the fixed-effect model (Yusuf et al, 1985). HRs
(representing the overall chance of dying for those allocated treat-
ment as compared with control) were also calculated for prespeci-
fied subgroups of patients using similar stratified methodology.
Chi-squared tests were used to test for gross statistical hetero-
geneity over all trials in a comparison (hetX2) and between subsets
of trials (interactionX2) (Early Breast Cancer Trialists' Group,
1990). These tests are aimed primarily at detecting differences in
effect size rather than direction and were chosen because qualita-
tive differences were not anticipated. Survival curves are presented
as simple (non-stratified) Kaplan-Meier curves. Improvements or
detriments to absolute survival rates were calculated by applying
the HR to baseline survival (Freedman, 1982); proportional hazards
are assumed. Baseline survivals of 45% at 2 years and 25% at
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Table 1
Cisplatin Carboplatin
Trial Combination Dose per cycle Cycles Dose per cycle Cycles
platinum + mg m2 mg m2
Single-agent chemotherapy
Royal Marsden 2 / 100 then 20 5 + 5 400 10
Wales / 100 5 400 5
GICOG / 100 5 400 4
Combination chemotherapy
MOCG CTX 100 6 300 6
EORTC CTX ADR HMM 100 6 350 6
Mayo Clinic CTX 60 12 150 12
GONO CTX ADR 50 6 200 6
NCIC CTX 75 6 300 6
SWOG CTX 100 6 300 6
GOCA CTX 80 6 350 6
Athens CTX EPI 100 6 300 6
Japan CTX ADR 50 6 250 6
ADR, doxorubicin; CTX, cyclophosphamide; EPI, epirubicin; HMM, hexamethylmelamine.
5 years were used based on the survival curves for the carbo-
platin/cisplatin comparison. All P-values quoted are two-sided
and unless otherwise specified X2 values are on one degree of
freedom.
RESULTS
In the first cycle of analyses, five treatment comparisons were
made. However, the comparison of single-agent and combination
non-platinum drugs (AOCTG, 1991) was not included in this
update as it was likely to yield minimal additional data and was
primarily of historical interest. For the remaining four compar-
isons, data were available for all but three trials (256 women) and
most were able to provide updated survival information. Four new
trials have been identified and included in the analyses.
Results are based on data from 37 RCTs, 5667 patients and 4664
deaths (compared with 33 trials, 5043 patients and 4195 deaths
previously). Tables providing details ofthe chemotherapy regimens
and doses used are available on request; some of this supplemen-
tary information has been published previously (AOCTG, 1991).
Single-agent non-platinum vs platinum-based
combination chemotherapy
Data were available from a total of 11 trials including 1329
patients and 1169 deaths (Bell et al, 1982; Decker et al, 1982;
Sturgeon et al, 1982; Williams et al, 1985; Gynaecological Group
COSA, 1986; Wilbur et al, 1987; Leonard et al, 1989; Masding et
al, 1990; Wadler et al, 1996; MRC Gynaecological Cancer
Working Party, unpublished data; Crowther, unpublished data).
Data were not available for two trials (99 patients) (Harvey et al,
1982; De Oliveira et al, 1990). One trial (Decker et al, 1982) of42
patients showed a conventionally significant benefit for combina-
tion chemotherapy, the remainder had wide confidence intervals
(CI) and were inconclusive. The overall results are inconclusive (P
= 0.23) but favour combination chemotherapy with an HR of0.93
(95% CI 0.83-1.05), equivalent to a 7% reduction in the overall
risk ofdeath. This translates to a suggested 3% benefit in absolute
survival at both 2 and 5 years, improving survival from 45% to
48% and from 25% to 28% respectively (95% CI, 7% benefit to
2% detriment). There was no gross statistical heterogeneity
between trials [hetX2 (10) = 16.42, P = 0.09]. Excluding the small
trial with the positive result gives an overall HR of0.96 (P = 0.51).
HR plots and survival curves are available on request.
Addition of platinum to a regimen
Data were available from all nine eligible trials including one new
trial, that compared a non-platinum drug regimen with the same
regimen plus cisplatin (Figure IA). A total of 1704 patients and
1428 deaths were included. The overall HR of0.88 favours the addi-
tion ofplatinum and is marginally significant (P = 0.02) (Figure lA
and B). The suggested 12% reduction in the risk ofdeath translates
to a 5% improvement in survival at both 2 (45-50%) and 5
(25-30%) years (95% CI 1-8% benefit). Although the best evidence
of a benefit is shown in the trials with a combination control arm
(HR = 0.85), there is no clear evidence that the results between the
two subsets oftrials differ (interaction X2 = 0.64, P = 0.42).
There is no gross statistical heterogeneity between those trials
with a combination control arm (P = 0.43), but for those with
single-agent control arms there is evidence of statistical hetero-
geneity (P = 0.02). Excluding the small positive trial (Decker et al,
1982) reduces the heterogeneity within this subset of trials
[X2 (3) = 2.18, P = 0.54] and does not alter the main results
materially, with an overall HR of0.90 (P =0.05).
Single-agent platinum vs platinum combination
Data were available from all eligible trials (Figure 2A) which
compared cisplatin and carboplatin either as single agents or each
in combination with the same drugs in multidrug regimens. This
included two new trials (Athanassiou et al, 1990; Skarlos et al,
1996) bringing the total number to nine and total patients and
deaths to 1095 and 894 respectively. One trial (GICOG, 1992)
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(No. events/no. entered)
Platinum No platinum O-E Variance
Added to single-agent
Loma Linda 4/4 7/7 0.96 2.05
OCSG 77-61-02 19/21 21/21 -8.54 7.30
COSA 2 167/183 165/187 3.82 82.36
Leo Laboratories 49/81 52/76 -6.25 24.79
MRC 44/51 44/49 -0.39 21.50
Sub-total 283/340 289/340 -10.39 137.99
Added combination
EORTC 55731 52/72 52/77 -0.01 25.86
GOG 47 208/244 215/251 -10.74 105.13
NCOG 5091 30/40 34/44 -2.70 15.83
SCOCSG 125/143 140/153 -20.99 65.05
Sub-total 415/499 441/525 -34.43 211.86
Total 689/839 730/865 -44.83 349.85
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Figure 1(A) HR plot for the addition of platinum to a regimen.
Added to single agent:
HR = 0.93 (95% Cl 0.78-1.10), X2(l) = 0.78, P = 0.38; HetX2(4) = 11.42, P = 0.02
Added to combination:
Platinum HR = 0.85 (95% Cl 0.74-0.97), X2(1) = 5.60, P= 0.02; Het X2(3) = 2.73, P= 0.44
No platinum Overall:
HR = 0.88 (95% Cl 0.79-0.98), X2(,) = 5.74, P= 0.02; HetX2(8) = 14.79, P= 0.06
Interaction X2(1) = 0.64, P = 0.42
Trials are ordered with the oldest at the top and most recent at the bottom. The HR is
given along the horizontal axis, with the vertical line drawn through unity indicating
equivalence or no difference between treatments. HRs to the right of this line favour the
_ single-drug regimens, whereas those to the left favour combination chemotherapy.
Each individual trial is represented by a square, the centre of which denotes the HR for
that trial, with horizontal bars whose extremities denote the 99% Cl and the inner tick
marks the 95% Cl. The size of the square is directly proportional to the amount of
48 60 information in the trial. The black diamond gives the overall HR when the results of all
trials are combined, the centre denoting the HR and the extremities the 95% Cl.
163 125 Included trials: Loma Linda: Wilbur et al (1987); OCSG - 77-61-07: Decker et al
128 105 (1982); COSA 2: Gynaecological Group COSA (1986), Leo Laboratories: Masding et al (1990); MRC: MRC Gynaecological Cancer Working Party, unpublished; EORTC
55731: De Oliveira et al (1990); GOG47: Omura et al (1986); NCOG5901: Turbow,
unpublished; SCOCSG: Trope et al, 1998. (B) Survival curve for the addition of
platinum to a regimen
showed a conventionally significant result at the 5% level, the
remainder were inconclusive. Overall, the results favour the use of
combination chemotherapy with a HR of 0.91 suggesting a 9%
reduction in the overall risk ofdeath, although this is inconclusive
(P = 0.21) (Figure 2A and B). This is equivalent to a 3% benefit in
survival at both 2 (45-48%) and 5 years (25-28%) (95% CI, 8%
benefit to 2% detriment). There is no evidence of gross statistical
heterogeneity between trials.
There is, perhaps, some visual suggestion of a qualitative inter-
action, that cisplatin-based trials favour combination chemotherapy
(HR =0.86, P =0.07), whereas carboplatin-based trials favoursingle-
drug therapy (HR = 1.05, P =0.21). However, thecarboplatin resultis
based on a relatively small number of events and CIs are wide such
that there is no clear evidence of a difference in effect between the
results forthese groups oftrials (interactionX2 = 1.76, P = 0.18)
If the Royal Marsden trial (Wiltshaw et al 1996) is excluded
from the analysis as was done previously (AOCTG, 1991),
because it compared high-dose cisplatin on its own with low-dose
cisplatin plus chlorambucil, the overall HR is 0.88 (P = 0.08) and
the HR for cisplatin-based trials is 0.80 (P = 0.02).
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(No. events/no. entered)
Combination Single O-E Variance
Cisplatin
Mt Sinai 17/18 15/18 1.08 7.91
GICOG 320/383 162/179 -21.27 98.97
Milan 14/23 15/21 -2.99 6.93
Royal Marsden 1 41/44 39/43 5.47 19.41
UK South West a 10/17 10/13 -3.27 4.29
Sub-total 402/485 241/274 -20.97 137.52
Carboplatin
SGCTG 69/76 77/85 1.69 36.16
HEGOG 1 37/57 39/73 -1.31 18.80
UK South West b 1/3 1/2 -0.35 0.43
Piraeus 122/156 12/20 3.07 6.49
Sub-total 122/156 129/180 3.11 61.88
Total 524/641 370/454 -17.87 199.40
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Carboplatin versus cisplatin
Data were available from 12 trials (Figure 3A)
trial (Gennatas et al, 1992), in total accountin,
and 1745 deaths. Data from one further trial
1992) including 157 women were not availa
regimens and drug doses used in these trials ar
The results of individual trials are very consist
evidence of statistical heterogeneity. There is n
any difference between cisplatin and carbopla
B) when given either as a single drug (HR = 1
combination (HR = 1.02, P = 0.74) (interacti(
0.96). The overall HR of 1.02 (P = 0.74) sugge
SIingtleo Figure2(A) HR plot forsingle-agent platinum vs platinum combination
chemotherapy.
Cisplatin:
HR = 0.86 (95% Cl 0.73-1.02), X2(,) = 3.20, P= 0.07; HetX2(4) = 6.84, P= 0.14
Carboplatin:
HR = 1.05 (95% Cl 0.82-1.35), X2(j)
= 0.16, P= 0.69; HetX2(3) = 1.75, P= 0.63
Overall:
HR = 0.91 (95% Cl 0.80-1.05), X2(j)
= 1.60, P = 0.21; HetX2() = 10.35, P = 0.24
Interaction X2(1)
= 1.76, P= 0.19
48 60 Included trials: Mt Sinai: Cohen et al (1983); GICOG: GICOG (1992); Milan: Tomirotti
et al (1988); Royal Marsden: Wiltshaw et al (1986); UK South West: Gilby et al,
142 112 unpublished; SGCTG: Rankin et al (1992); HECOG1: Skarlos et al (1996); Piraeus:
70 51
Athanassiou et al (1990). (B)
Survival curve for single-agent platinum
vs platinum
combination chemotherapy
cisplatin, but the confidence intervals are such that it could be
including one new consistent with modest benefits ofeither drug. In terms ofabsolute
o9 niews survival at both 2 and 5 years, the 95% CI is consistent with
g(BePpomm eta improvements in overall survival of 3% benefit for cisplatin and
ble. DBetailse of 4% benefit forcarboplatin. Lble. Details of the
re given in Table 1. Treatment effects in different subgroups
tent and there is no
Io good evidence of Different patient subgroups were analysed using data provided for
tin (Figure 3A and 11 ofthe trials included in the carboplatin/cisplatin comparison. No
.01, P = 0.92) or in such analyses had been carried out previously. Figure 4A-C indi-
Dn X2 = 0.003, P = cates that there is no good evidence that any group of women spec-
-sts a 2% benefit of ifiedby age, stage, performance status, residual tumourbulk, extent
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(No. events/no. entered)
Carboplatin Cisplatin O-E Variance
Single-agent
Royal Marsden 2 58/67 57/64 -0.02 28.62
Adams 37/45 33/43 0.68 17.41
GICOG 72/88 73/85 0.24 36.16
Sub-total 167/200 163/192 0.90 82.18
Combination
MOCG 23/27 23/29 -0.78 11.31
EORTC 126/169 120/170 4.24 61.32
MAYO 42/50 43/54 4.51 20.78
GONO 65/83 67/82 -2.67 32.90
NCICCTG 189/224 188/223 -2.76 94.08
SWOG 156/171 149/171 4.65 75.89
GOCA 44/87 41/86 2.26 21.18
Athens 62/73 64/76 -0.12 30.92
Japan 5/29 5/23 -1.16 2.32
Sub-total 712/913 700/914 8.18 350.70
Total 879/1113 863/1106 9.08 423.88
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Carboplatin Figure 3 (A) HR plot for cisplatin vs carboplatin-based chemotherapy. Cisplatin Single agent:
HR = 1.01 (95% Cl 0.81-1.26), X2(1) = 0.01, P = 0.92; HetX2(2) = 0.02, P = 0.99
Combination:
HR = 1.02 (95% Cl 0.92-1.13), X2(1) =0.19, P=0.66; HetX2(8) = 2.54, P= 0.96
Overall:
HR = 1.02 (95% CI0.93-1.12), X2(1) = 0.19, P= 0.66; HetX2(,,) = 2.57, P= 0.99
Interaction X2(1) = 0.01, P = 0.92
Included trials: Royal Marsden 2: Taylor et al (1994); Adams: Adams et al, (1989);
GICOG: Mangioni et al (1989); MOCG: Anderson et al (1988); EORTC: ten Bokkel 48 60 Huinink et al (1988); MAYO: Edmonson et al (1989); GONO: Conte et al (1991);
NCICCTG: Swenerton et al (1992); SWOG: Alberts et al (1992); GOCA: Meerpohl et al
242 196 (1990); Athens: Gennatas et al (1992); Japan: Kato et al (1988). (B) Survival curve for
254 197 cisplatin vs carboplatin-based chemotherapy
of operation, histology or grade will do any better or worse when
treated with either cisplatin or carboplatin. There is perhaps some
suggestion that stage II tumours may benefit more from cisplatin.
However, very few stage II tumours were included, the CIs are
wide and it is difficult to draw any conclusions from the result.
DISCUSSION
The results for the comparison ofsingle non-platinum drugs versus
platinum-based combinations, which is undoubtedly the most clin-
ically heterogeneous comparison, tend to favour platinum combi-
nation chemotherapy. However, the confidence limits are such that
the results remain inconclusive. Forthe comparison ofthe addition
ofplatinum to otherwise similar drug regimens, with the inclusion
of one new trial and additional follow-up, the results are now
marginally significant (at conventional levels) in favour of plat-
inum. An absolute benefit of around 5% at 2 and 5 years is
suggested. Given that there are now few patients 'at risk' for
whom additional follow-up will be possible in either of these
comparisons, it is unlikely that these results will change over time
unless furtherlarge trials emerge. Thus, these results will probably
remain the best and least biased estimates of the benefits of
platinum-based therapy over non-platinum regimens (which were
mostly based on alkylating agents). When interpreting these
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Figure 4 (A) Treatment effect by age, performance status, residual bulk. (B) Treatment effect by stage, grade, extent of operation. Complete = total
abdominal hysterectomy + bilateral salpingo oophorectomy; none no operation, exploratory or biopsy only, incomplete
= any other operation. (C) Treatment
effect by histology
results, however, it should be appreciated that many women in
these trials are likely to have received platinum on relapse from
which they may have derived a late benefit, and that drugs were
sometimes administered at doses and schedules that would not be
considered adequate today. Thus, in effect these comparisons are
probably comparing a policy of immediate versus delayed plat-
inum-based therapy. The results, therefore, suggest that the policy
of giving immediate platinum-based treatment results in better
overall survival than delaying such treatment until relapse.
The results for the comparison of single-agent platinum with
platinum in combination are inconclusive, but for the cisplatin-
based trials there is a strong trend in favour of combination
chemotherapy. These results are driven largely by the GICOG
multicentre Italian trial, which contributed 50% of the total infor-
mation. In most of these studies, the dose of platinum used as a
single agent was lower than is currently standard, and the differ-
ence could be attributable to the higher total drug dose rather than
combination chemotherapy per se. For these trials, there are
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reasonable numbers of patients for whom further follow-up is
possible. It may, therefore, be important to update this analysis in
future and to incorporate data from currently ongoing trials. If, as
these results suggest, there may be a modest advantage of combi-
nation chemotherapy, then it is important to have a reliable esti-
mate of effect with tight confidence intervals as the trade-offs
involved and the subsequent choice between the two types oftreat-
ment is not necessarily straightforward. In such circumstances,
precise estimates of any survival differences are essential.
The comparison of cisplatin and carboplatin shows no obvious
advantage of one compound over the other in terms of survival.
These results appear very consistent across trials. Data were not
available for one trial (Belpomme et al, 1992) whose preliminary
results showed a significant prolongation of median survival for
cisplatin. As far as is known, this trial, which prohibited crossover
to cisplatin, has never been published in full. As in other compar-
isons, this meta-analysis compares treatment policy, in this case
the policy of immediate cisplatin versus immediate carboplatin.
The individual patient data collected for this meta-analysis show
that crossover rates during the treatment period were not excessive
and are comparable on each treatment arm. With the exception of
two trials (Taylor et al, 1994; Edmonson et al, 1989), comprising
10.6% of the total patients, such crossover rates were less than
10%. However, it remains likely that patients may have been
treated with the alternative platinum analogue on relapse if this
happened outside the period of primary treatment. Thus, the
comparison could, in fact, be one of immediate versus delayed
treatment with the two platinum compounds. It will be important
to update this analysis in future, looking at long-term survival,
especially as the results are somewhat inconsistent with those
found in testicular cancer, in which cisplatin has been shown to be
superior to carboplatin (Bajorin et al, 1993; Horwich et al, 1994).
However, the consistency of the results in the subgroup analyses
lends support to the interpretation that neither drug is superior in
terms of improving overall survival in advanced ovarian cancer.
There was no good evidence that cisplatin was more or less effec-
tive in any particular predefined subgroup of patients and, there-
fore, no good grounds for selecting women on the basis of age,
performance status, extent of resection, tumour stage, residual
bulk, grade or histology to receive one or other treatment. The
somewhat extreme HR in favour ofcisplatin in stage II tumours is
based on very small numbers of patients. Owing to this and the
increased possibility of false-positive results because of multi-
plicity of subgroup analysis, this result should certainly not be
regarded as anything more than hypothesis generating. It should be
noted that trials included in the meta-analysis do not do not include
recent and ongoing randomized trials using taxanes as a compo-
nent of combination chemotherapy. Future updates will aim to
include data from these trials.
Implications for research
Currently, much research effort is focused on paclitaxel, but it is
not yet clear what should be used as the appropriate 'control' arm
in these trials. These results suggest that this should be either plat-
inum as a single agent or in combination. If the latter, this should
probably be the CAP regimen which a separate meta-analysis has
shown to be superior to CP (Ovarian Cancer Meta-analysis
Project, 1991). However, in that meta-analysis, the doses of
cisplatin and cyclophosphamide were similar in the two treatment
arms and the observed difference could, therefore, have been
C) Cancer Research Campaign 1998
attributable to either the addition of doxorubicin or to higher total
doses of drug on the CAP arm. The full results of ICON2 (Torri
et al, 1996), comparing CAP with single-agent carboplatin, are
awaited with interest. When these results are available, taken
together with the results presented here, the best 'standard' therapy
may be identified which can be used as the baseline against which
to measure current and future drug development.
Implications for practice
Just as no clinical trial can provide prescriptions of how to treat
individual cases, neither can a meta-analysis. Although not conclu-
sive, the results suggest that platinum-based chemotherapy is better
than non-platinum therapy, that platinum combinations may offer
improved survival over single-agent platinum and that cisplatin and
carboplatin are equally effective. However, patients are not uniform
in their preferences and the trade-offs between choosing more and
less intensive therapy are not always straightforward.
Ultimately, the treatment chosen is to be decided by the patient
and clinician and will depend on many factors including toxicity
and quality of life in addition to survival estimates. However, the
results of this meta-analysis provide the current most reliable esti-
mates of the relative survival benefits of the treatments studied to
be used as part of this decision-making process.
ORGANIZATIONS AND GROUPS THAT
COLLABORATED IN THIS META-ANALYSIS
British Medical Research Council (MRC), Eastern Cooperative
Oncology Group (ECOG), European Organisation for Research
and Treatment of Cancer (EORTC), German Ovarian Cancer
Study Group (GOCA), Gruppo Intergionale Cooperativo
Ginecologia (GICOG), Gruppo Oncologica Nord Ovest (GONO),
Gynecologic Oncology Group (GOG), Gynaecological Group
Clinical Oncological Society of Australia (COSA), Hellenic
Cooperative Oncology Group (HECOG), Manchester Ovarian
Cancer Study Group (MOCSG), Mario Negri Institute, Mayo
Clinic, National Cancer Institute of Canada Clinical Trials Group
(NICIC, CTG), Northern Californian Oncology Group (NCOG),
Scottish Gynaecological Cancer Trials Group (SGCTG),
Southwest Oncology Group (SWOG) and Swedish Cooperative
Ovarian Cancer Study Group (SCOCSG).
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